Tuesday, 9 February 2010
Amanda Ellis
BENITEC received a boost last week on news that global pharmaceutical giant Pfizer has exercised a $US145 million option with Benitec spin-off Tacere Therapeutics for the development of hepatitis C virus compounds which use Benitec technology.
You are not logged in or not authorised to view this page.
Get Your FREE 30 Day Trial Now!
|
|
|
OR
Click here to read the rest of today's news stories.
| 
